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Transformed cells can develop drug resistance via 
repair mechanisms that counteract the DNA damage from 
chemotherapy or radiation therapy. Disruption of DNA 
repair pathways can cause mis-repair that is cytotoxic [1]. 
Specific DNA repair inhibitors might thus be combined 
with DNA-damaging agents for improved therapy. In 
addition, some cancer cells have a reduced repertoire of 
DNA damage responses, which provides other therapeutic 
openings. Recent studies show that many DNA repair 
proteins are associated with those involved in RNA 
metabolism and transcriptional regulation, including 
within the nucleolus [2].
The base excision DNA repair (BER) pathway 
handles simple alkylation and oxidative lesions arising 
from both endogenous and exogenous sources, including 
cancer therapy agents. The core BER enzyme Ape1 also 
contributes to the regulation of oxidative stress responses 
and has other non-repair activities, such as regulating the 
expression of chemoresistance genes (i.e. MDR1) [3]. 
Ape1 is thus an emerging target for combination therapy 
of different cancers.
Ape1 can function as a “redox factor” [1] that 
stimulates DNA binding by transcription factors involved 
in cancer promotion and progression, such as NF-ĸB, 
Egr-1, Hif-1α, Nrf1 [3], thus influencing inflammatory 
and metastatic processes. A third poorly characterized 
Ape1 function is its transcriptional activity on genes 
such as SIRT1 and those encoding some mitochondrial 
proteins (Tfam, Cox6c, and Tomm22) [2]. Moreover, 
Ape1 regulates the expression of tumor-progression and 
therapy-resistance genes through transcriptional effects 
(on the VEGF and MDR1 genes, for example) and 
post-transcriptional mechanisms through direct mRNA 
binding by Ape1 (e.g. c-Myc) [3]. These observations 
prompt a new model that links DNA damage responses 
and the modulation of target genes, which may provide 
chemoresistance during tumor development.
Cancer-associated Ape1 variants are often altered in 
the protein’s DNA repair domain, with some exhibiting 
nuclease defects in vitro [4]. Up-regulation of Ape1 
correlates with the onset of chemoresistance in ovarian, 
hepatic and neurologic tumors, while inhibition of the 
protein with small compounds, or the downregulation 
of its expression, sensitizes cells to DNA-damaging 
chemotherapeutic drugs and ionizing radiation [3]. 
Which Ape1 activity is involved in cancer development 
or chemoresistance remains unknown. We discovered a 
function of Ape1 in rRNA metabolism involving direct 
rRNA binding and interaction with NPM1, which is 
required for retaining Ape1 in the nucleolus. A role 
in rRNA metabolism may explain the altered Ape1 
expression observed in different tumors [3]. Although 
knowledge of Ape1’s possible function in the nucleolus 
is incomplete, the protein retained there may provide an 
immediate source of additional enzyme for BER in cells 
subjected to genotoxic stress. The interaction with NPM1 
also stimulates Ape1 DNA repair activity; accordingly, 
NPM1–/– cells show impaired BER activity [5]. The 
NPMc+ mutation (frequently found in blasts from AML 
patients) relocalizes the protein to the cytoplasm taking 
Ape1 with it [7]. NPM1c+ tumors have a good prognosis 
for chemotherapy [3], perhaps related to nuclear deficiency 
of Ape1. Conversely, in solid tumors such as hepatic 
and ovarian cancers, Ape1 and NPM1 up-regulation is 
linked to increased chemoresistance [3]. Even without 
a genotoxic challenge, cell lines expressing an Ape1 
variant that does not interact with NPM1 display reduced 
proliferation [5]. Thus, the Ape1-NPM1 association 
highlights the role of Ape1 dysregulation in cancer biology 
(Fig. 1). Reduced NPM1 levels may lead to genomic 
instability through impairment of BER and increased DNA 
damage. As a consequence, the DNA damage response 
blocks cellular proliferation. A few cells may escape the 
blockage and establish an immortalized clone susceptible 
to oncogenic transformation. Alternatively, the presence of 
high NPM1 and Ape1 levels may limit DNA damage and 
the DNA damage response, thus supporting cell survival 
and generating a permissive condition for transformation. 
These studies further suggest that other alterations of the 
Ape1 interactome may lead to the impairment of BER as 
observed for the NPMc+ mutation. We identified novel 
Ape1 acetylation sites dysregulated in TNBC, responsible 
for stimulating the endonuclease activity of the protein and 
its binding to NPM1 and RNA molecules [5]. Therefore, 
the modulation of Ape1 modifications and interactions 
affects BER activity and is linked to tumorigenesis.
In the last decade, several laboratories identified 
inhibitors of the Ref-1 redox activity (e.g., E3330, RN81 
and resveratrol), or inhibitors of the Ape1 DNA repair 
activity (i.e. lucanthone, CRT0044876, myricetin, etc.) [3]. 
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However, these compounds have limited specificity: the 
activities are not unique to transformed cells. A recently 
identified role of Ape1 in telomere maintenance [7] might 
provide other interactions that could be usefully disrupted 
in cancer cells.
Because multiple cellular functions can be affected 
by inhibiting Ape1, targeting its interactions with other 
proteins such as NPM1 may represent a powerful strategy 
for developing more specific anticancer drugs. Therefore, 
current research must focus on understanding all the roles 
of Ape1 in cancer resistance, including its role in the 
nucleolus, and the fine-tuning mechanisms responsible for 
regulation of these activities.
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Figure 1: The relative contribution of NPM1 and Ape1 
expression to cellular transformation: a new model for 
the role of Ape1 in tumorigenesis. 
